Biology and pathogenesis of the myelodysplastic syndromes.

Alan F. List,A. Jacobs

IF: 5.385

1992-02-01

Seminars in Oncology

Abstract:

What problem does this paper attempt to address?

Treatment of hepatocellular carcinoma: beyond international guidelines

Massimo Colombo,Angelo Sangiovanni

DOI: https://doi.org/10.1111/liv.12713

Abstract:The management of hepatocellular carcinoma (HCC) is decided according to evidence-based recommendations generated by international societies: according to these recommendations, the tumour stage, as determined by the Barcelona clinical liver cancer (BCLC) score, divides patients into five prognostic categories, each with a distinct treatment indication. Radical therapies such as hepatic resection, orthotopic liver transplantation and percutaneous local ablation are strongly indicated in patients with very early and early stage tumours (BCLC O and A), a choice which mainly depends on a combination of tumour volume, status of underlying liver disease, the presence of comorbidities and the patient's age. Although radical therapies provide a survival rate of between 50% and 75% at year five in well selected patients, tumour recurrence is frequent following resection and ablation compared to transplantation (70% vs. 10% respectively), which has the additional advantage of preventing morbidity and mortality from portal hypertension. Generally, while radical therapies are contraindicated in patients with a large tumour burden, such as those with intermediate stage BCLC B, survival in the subset of these patients with well compensated cirrhosis may improve from 16 to 20 months, on average, following repeated treatments with transarterial chemoembolization (TACE). Survival may also improve in patients who are in poor condition or who do not respond to TACE and in those with an advanced HCC (BCLC C) following oral therapy with the multikinase inhibitor sorafenib. However, because most recommendations are based on uncontrolled studies and expert opinions rather than well designed, high powered randomized controlled trials, treatment criteria need to be adapted to special groups because real life cohorts do not match the selection criteria suggested by the guidelines. Indeed, up to one-third of patients with early stage tumours who are unfit for radical therapy because of advanced age, the presence of significant comorbidities or a strategic location of the nodule, are forced to receive palliative care. BCLC A patients with moderate portal hypertension and certain BCLC B patients could still be eligible for hepatic resection if a chance for 50% survival at 5 years is still perceived as being cost-effective by both the patient and caregivers.
Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study

L. Canova,M. Iavarone,E. Alimenti,B. Antonelli,A.M. Ierardi,S. Crespi,M. Viganò,G. Cabibbo,A. Vitale,A. Sangiovanni,P. Lampertico

DOI: https://doi.org/10.1016/j.dld.2024.01.140

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Background and aim Treatment strategy of hepatocellular carcinoma (HCC) is a complex decision-making process that should consider several variables in clinical practice. Recently, a “multiparametric therapeutic approach” has been proposed (Vitale A, Cabibbo G et al Lancet Oncol 2023). In this approach, the feasibility of all treatments is evaluated systematically in a hierarchical order, to match each patient with the optimal therapy. The aim of the study is to validate the reliability of the new multi-parametric decisional framework (MPDF) and the impact of the different variables included in the framework on the final treatment decision in clinical practice. Methods This is a prospective ongoing study with a first monocentric phase (A) and a second multicentric validation phase (B). Primary endpoints are: 1) adherence to MPDF for treatment allocation and 2) identification of the relative weight of variables involved in this multiparametric evaluation to predict treatment decision, while secondary endpoints are overall survival (OS) and radiological response after treatment. The study includes all consecutive patients with HCC managed in each center from September 1st, 2023. The disease is staged according to Barcelona Clinic Liver Cancer (BCLC) classification, while patient's characterization is conducted by Charlson Comorbidity Index (CCI), modified CCI (mCCI), Liver Frailty Index (LFI), Child-Pugh (CPT) and ALBI scores, MELD and skeletal muscle mass index (SMI) by CT-evaluation. Each patient is allocated to treatment according to MPDF, BCLC 2022 was used as benchmark of treatment allocation. Results As of November 1st, 2023, 48 patients were recruited into phase A of the study [median age 70 (52-87) years, 81% male, 37% HCV-Ab positive, 27% first diagnosis/treatment of HCC]. Thirteen (27%) patients were classified as BCLC 0, 17 (35%) as BCLC A, 6 (12.5%) as BCLC B, 6 (12.5%) as BCLC C and 6 (12.5%) as BCLC D. The median CCI was 8 (4-13), the median LFI was 4.15 (2.99-4.81) which corresponds to a pre-frail condition. Thirty-nine (81%) patients were in CPT class A, 7 (15%) in B and 2 (4%) in C, while 32 (67%) were classified ALBI grade 1 and 16 (33%) ALBI grade 2, and finally the median MELD score was 8.5 (6-22). Forty-four (92%) patients received treatment through a multidisciplinary team (MDT). According to the MPDF, 9 (19%) patients were allocated to liver transplant, 5 (10%) to laparoscopic surgical resection, 10 (21%) to microwave thermal ablation (MWTA), 7 (15%) to transarterial treatments (4 TACE and 3 TARE), 3 (6%) to other locoregional therapies (2 MWTA+TACE and 1 electrochemotherapy), 6 (13%) to systemic treatment and 5 (10%) to palliative care only. In 4 cases, the MDT decided for follow-up at 3 months and subsequent reassessment. The reason why each therapy was excluded for each patient is shown in Table 1. The treatment allocation was coherent to the BCLC 2022 treatment allocation system in the 69.2% for BCLC 0, 82.4% for BCLC A, 83.3% for BCLC B, 66.7% for BCLC C and 100% for BCLC D. Conclusions Preliminary data of our ongoing prospective study suggest that personalized approach for HCC treatment by MPDF is feasible in clinical practice and might help ensuring a customized approach in a standardized framework. Updated data will be presented at the meeting.

gastroenterology & hepatology
Hyperpolarization-activated inward chloride current in protoplasts from suspension-cultured carrot cells

J. Barbara,H. Stoeckel,K. Takeda

DOI: https://doi.org/10.1007/BF01507849

1994-09-01

PROTOPLASMA

Abstract:
Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice

E. Alimenti,M. Iavarone,L. Canova,M. Bruccoleri,B. Antonelli,A.M. Ierardi,S. Sangiovanni,P. Lampertico

DOI: https://doi.org/10.1016/j.dld.2024.01.143

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Introduction In 2022 the BCLC staging and treatment algorithm for hepatocellular carcinoma (HCC) management has been updated, granting for higher flexibility and customized management with a multidisciplinary decision process in the choice of the therapeutic strategy for HCC patients as compared to the 2018 version. Aim To evaluate the ability to adhere to BCLC 2022 in daily clinical practice as compared to the BCLC 2018 and the impact on patients’ overall survival (OS). Methods We retrospectively evaluated data of 806 prospectively enrolled (year 2006 to 2022) patients with de novo HCC (Table 1) in different stages according to BCLC: 571 0-A, 133 B, 85 C and 17. First line treatment allocations were discussed by a multidisciplinary team (MTD), following updated recommendations and guidelines. All patients were followed until death or end of follow-up. Results Overall, the adherence to BCLC increased from 50% for the BCLC 2018 to 68% for the BCLC 2022 (p<0.001) considering all stages of HCC: 48% vs 71% stage 0/A (p<0.001), 50% vs 61% stage B (p=0.06), 59% vs 59% stage C (p=NS), 74% vs 74% for stage D (p=NS). Among BCLC 0/A patients, 131 (32%) were treated with TACE, which is the second choice of treatment according to BCLC 2022, while among BCLC B patients, 5 (6%) underwent LT and 10 (12%) were treated with systemic therapy, which are now considered treatment options for this stage in selected patients. The expected survival rate following the BCLC 2018 recommendations remains unchanged by adhering to the BCLC 2022 update [74.5% vs 75.2% at year 2 (p=NS) and 41.4% vs 44.6% at year 5 (p=NS), respectively]. Finally, the rate of “upward stage migration” was similar by BCLC 2022 or BCLC 2018 (12% vs 14%, p=ns), while the rate of “downward stage migration” was lower with the new one (19% vs 36%, p<0.001). Overall, the 2-year survival rate of patients treated outside the BCLC 2022 recommendations did not significantly differ from those treated according to the updated algorithm (76% vs 74.5%, p=NS). In BCLC B and BCLC C, an upward stage migration was associated to higher rates of 2-year survival (93.5% vs 60.6%, p=0.002 for BCLC B and 36.9% vs 27.4%, p=0.01 for BCLC C), while there was no difference for stage 0/A between those treated outside and those treated according to the BCLC 2022. Conclusions The BCLC 2022 updated version of HCC staging and treatment system allowed a greater adherence to the algorithm in clinical practice, mainly in the early stages, without adversely affecting the survival of patients. In the intermediate and advanced stages, the access to more radical treatment could offer a survival benefit.

gastroenterology & hepatology
Compliance to the American Association for the Study of Liver Diseases (AASLD) guidelines and its impact on overall survival in patients with hepatocellular carcinoma.

Ashish Manne,Madhuri S Mulekar,Daisy E Escobar,Pranitha Prodduturvar,Yazan Fahmawi,Phillip Henderson,Osama Abdul-Rahim,Zeiad Hussain,Spencer Liles,Annabelle Fonseca,John Harrison Howard,Wadad Mneimneh,Robert Gilbert,Sachin Gopalkrishna Pai,Cindy Nelson,Moh'd M. Khushman

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.e16609

IF: 45.3

2020-05-20

Journal of Clinical Oncology

Abstract:e16609 Background: The Barcelona-Clinic Liver Cancer (BCLC) staging based management proposed by AASLD depends on baseline liver function and performance status of the patient in addition to tumor characteristics. Low adherence to AASLD guidelines, especially in advanced staged tumors, can be ascribed to suboptimal revision/updates of the guidelines reflecting the advancements in hepatocellular carcinoma (HCC) management. Here, in addition to the adherence rate, we explored the overall survival of patients with HCC according to first-line treatment modality compliance to AASLD guidelines. Methods: This is a retrospective study conducted at the University of South Alabama/Mitchell Cancer Institute. Between 2017 and 2019, 148 unique treatment-naïve patients with HCC were identified. Patients were staged according to the BCLC staging system and their compliance with suggested first-line treatment modality according to AASLD guidelines was noted. Overall survival was explored and differences between overall survival rates of compliant and non-complaint patients were compared using the log-rank Wilcoxon test. Results: In our cohort, the median age was 72.5 years (range 38-90). Males represented 80%. Caucasians, African Americans, and other ethnicities (e.g. Asians) represented 68%, 30% and 2% respectively. The overall adherence rate was 83%. The adherence rate according to BCLC stage 0, A, B, C and D was 100%, 97%, 77%, 77% and 38% respectively. Compliance vs. non-compliance to AASLD guidelines showed no significant difference in overall survival of patients with BCLC stage 0-A, B and C. In patients with BCLC stage D (N = 13), compared to patients treated in compliance to AASLD guidelines (N = 5), patients treated in non-compliance (N = 8) had better overall survival (2.2 vs. 5.2 months, p = 0.0012). Conclusions: In our cohort, the adherence rate to AASLD treatment guidelines in patients with BCLC stage D was very low at 38%. Lack of adherence in this group of patients translated into better overall survival. The current AASLD guidelines for the management of HCC have several limitations, especially for advanced stages. In the last few years, the FDA approved several tyrosine kinase inhibitors, immune checkpoint inhibitors and the monoclonal antibody, ramucirumab. This expansion generated the need for periodic updates/revisions of consensus guidelines.

oncology
Hepatoma Today: Therapeutic Experiences of Multimodal Approach

Zhao-You Tang,Giammaria Fiorentini

DOI: https://doi.org/10.1177/030089169307900302

1993-06-01

Tumori Journal

Abstract:Aims and Background Hepatocellular carcinoma (HCC) ranks third of cancer deaths in China, it kills 100,000 patients every year. In Italy HCC is an increasing malignant tumor and kills about 7000 patients every year. Fortunately, due to a multimodal approach to the treatment of this fatal disease, HCC has been changed from « Incurable » to « partly curable ». The authors report and comment the methods and the strategies that have been used to increase the cure-rate of HCC. Methods The actual approaches, developed in the last thirty years mainly in China, included: screening of cirrhotic patients, early resection, new surgical criteria for cirrhotic liver, early detection of subclinical recurrence and re-resection, multimodality treatment for cytoreduction of huge HCC, sequential resection after cytoreduction of unresectable HCC, targeting therapy using radiolabelled antibodies and lipiodol, transarterial embolization, radiotherapy combined with Chinese herbs, other regional cancer therapy and biological response modifiers. Results Are that these methods have reached a marked increase series 5-year survival rate and number of 5-year survivors in more expert institutions. Conclusions We conclude that further biological and genetic studies on HCC are warranted and that it is mandatory to perform large clinical randomized trials comparing the more promising treatments.

oncology
Multimodal treatment confers best overall survival results in patients with huge hepatocellular carcinoma: a systematic review and network meta-analysis

Andrea Chierici,Mohamed El Zibawi,Guido Liddo,Rodolphe Anty,Stefano Granieri,Patrick Chevallier,Antonio Iannelli

DOI: https://doi.org/10.1016/j.hpb.2024.04.002

Abstract:Background: Huge (>10 cm) hepatocellular carcinoma is burdened by elevated mortality due to its peculiar characteristics and delayed diagnosis. Liver resection is considered the gold standard although survival is poor. Recently, some different strategies have been evaluated to improve results in tumor recurrence and survival. The aim of this research is to identify which strategy offers the best results in terms of overall survival for resectable huge hepatocellular carcinoma. Methods: A systematic review and network meta-analysis of 13 studies was conducted from PubMed, Embase, Scopus, Cochrane Library, and Web of Science databases including research comparing two or more treatments to manage huge hepatocellular carcinoma. Results were synthesized through forest plots and risk of bias assessed with the CINeMA framework as recommended. Results: The association of liver resection and transcatheter arterial chemoembolization confers a significant improvement in survival compared to liver resection alone (HR: 0.55) while transcatheter arterial chemoembolization, radioembolization, and ethanol ablation alone were associated to decreased overall survival. Within-study bias, indirectness and incoherence were the domains mainly affected by concerns in risk of bias analysis. Conclusion: Multimodal treatment including liver resection and transcatheter arterial chemoembolization increases survival in patients with resectable huge hepatocellular carcinoma.
Clinical events after TIPS: correlation with hemodynamic findings.

P. T. ter Borg,M. V. van Donselaar,H. V. van Buuren

DOI: https://doi.org/10.1016/s0016-5085(98)70059-9

IF: 29.4

Gastroenterology

Abstract:
Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective

Anish Narayanan,Andres Garza-Berlanga,Jorge Lopera

DOI: https://doi.org/10.21037/apm-23-294

Abstract:Background and objective: It is estimated that 35-40% of hepatocellular carcinoma (HCC) patients present with multiple nodules at the time of diagnosis. Treating multifocal disease is difficult given patient population heterogeneity. Multiple interventional radiological (IR) options, including ablation, transarterial chemoembolization (TACE), and transarterial radioembolization (TARE), are available, each with its own merits and limitations. Our aim is to explore the current state of the literature to identify where each of these options is best applied to multifocal HCC management. Methods: A narrative literature review of 107 papers was performed in PubMed. Articles from 2010 and newer were used for clinical data and for classification/scoring system details. The majority of the keywords for searches include the treatment modality name alongside terms such as "HCC", "multifocal", or "multinodular". Key content and findings: Ablation is a curative option for Barcelona Clinic Liver Cancer (BCLC) A disease and is appropriate when liver transplantation (LT) is impractical. It is ideal in disease with ≤3 nodules (each <3 cm) preferably confined to one segment. TACE [conventional TACE (cTACE), drug-eluting bead TACE (DEB-TACE), balloon-occluded TACE (B-TACE), and less so hepatic arterial infusion chemotherapy (HAIC)] is the major workhorse for multifocal BCLC B disease, in pre-transplant downstaging, and in advanced disease palliation. The Kinki BCLC B subclassification can guide TACE subtype selection. TACE response can be assessed over 2-3 sessions per modified Response Evaluation Criteria in Solid Tumors (mRECIST) and patient session tolerance. TARE is an option for BCLC C disease, with BCLC A/B applications limited by radiation induced liver disease (RILD). Pseudo-ablative techniques like sub-selective TARE (sTARE) are promising but are unproven and less useful in multinodular disease. Finally, combination therapies [TACE + ablation, liver resection (LR) + ablation/TACE] are an exciting option but warrant further study. Conclusions: Multifocal HCC remains challenging to manage. While BCLC is a useful starting point, the patient's tumor imaging characteristics and clinical circumstances must be considered when selecting the appropriate treatment modality.
Merits and boundaries of the Barcelona Clinic Liver Cancer Staging and Treatment Algorithm: learning from the past to improve the future with a novel proposal.

Franco Trevisani,Alessandro Vitale,Masatoshi Kudo,Laura Kulik,Joon-Won Park,David J Pinato,Umberto Cillo,David J. Pinato

DOI: https://doi.org/10.1016/j.jhep.2024.01.010

IF: 25.7

2024-01-24

Journal of Hepatology

Abstract:Summary This Expert Opinion article thoroughly analyses the Barcelona Clinic Liver Cancer (BCLC) staging and treatment algorithm for hepatocellular carcinoma (HCC) that, since 1999, has standardised the HCC management, offering a structured approach for the prognostic evaluation and treatment recommendations of patients with HCC. The first part of the article presents the strengths and evolutionary improvements of the BCLC staging system. Nevertheless, both patient characteristics and treatments available have changed in the last two decades, limiting the role of the BCLC for treatment allocation in a growing number of patients. As therapeutic options expand and become more effective, the stage-linked treatment decision-making algorithm may lead to undertreatment and suboptimal outcomes for patients with disease beyond early-stage HCC. Consequently, strict adherence to BCLC is limited in expert centres, particularly for patients diagnosed beyond early-stage HCC. Although the BCLC system remains the benchmark against which other therapeutic frameworks must be judged, the era of precision medicine requires patient-tailored therapeutic choices formulated by a multidisciplinary tumour board rather than a stage-dictated allocation of treatment. Acknowledging this conceptual difference in clinical management, the second part of the article describes a novel "multiparametric therapeutic hierarchy", which integrates a comprehensive patient clinical assessment, biomarkers, technical aspects and considerations on resource availability. Lastly, considering the increasing efficacy of locoregional and systemic treatments, the concept of "converse therapeutic hierarchy" is introduced. These treatments can increase the feasibility (conversion approach) and effectiveness (adjuvant approach of systemic therapy) of potentially curative approaches, improving the outcome of HCC management.

gastroenterology & hepatology
A Multidisciplinary Team Approach to the Treatment of Liver Cirrhosis

Yue-Rong Zhang,Hui Wang,Ning Zhou,Yao-Di Zhang,Yan Lin,Li-Yang Wu,Shi-Fang Wei,Yan-Yun Ma,Chun-Xia Wang

DOI: https://doi.org/10.2147/jir.s328334

IF: 4.5

2021-10-01

Journal of Inflammation Research

Abstract:OBJECTIVE: To explore the feasibility of treating cirrhosis using a multidisciplinary team approach (MDT) and to pinpoint the key factors influencing its implementation.METHODS: The data of 307 patients with decompensated cirrhosis were studied retrospectively. Patients who received more than two treatment measures were assigned to the MDT group (n=228), and patients who received symptomatic medical drug treatment only were assigned to the traditional treatment group (n=79). The follow-up period ranged from 4 to 10 years, and the average follow-up period was 5.7 years. The results of the biochemical tests for hepatitis B virus deoxyribonucleic acid, hepatitis C virus ribonucleic acid, and autoantibodies to liver disease were analyzed.RESULTS: The differences in gender and Child-Pugh grade of liver function between the two groups were not statistically significant. The MDT group had obvious advantages over the traditional treatment group in occupational composition, etiology composition, 5-year survival rate and annual hospitalization times. The leading causes of death in the MDT group, in descending order, were liver cancer, infection, mesenteric thrombosis, and non-hepatic disease, and, in the medical treatment group, they were liver failure, gastrointestinal bleeding, infection, and liver cancer. There was a significant statistical difference between the two groups (p < 0.05). In the multidisciplinary treatment, etiological treatment was the most widely used treatment, accounting for 79.8%, followed by endoscopic treatment (33.3%), peritoneal drainage and ascites reinfusion (25%), splenectomy combined with devascularization (11.4%) and stem cell transplantation and liver transplantation (1.8%).CONCLUSION: An MDT can improve the efficacy and prognosis of patients with cirrhosis and improve patient compliance. After multi-disciplinary intervention, the mortality spectrum of long-term survival patients with cirrhosis changes, and the mortality rate of liver cancer and non-liver disease increases.

immunology
Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy

Alessandro Vitale,Franco Trevisani,Fabio Farinati,Umberto Cillo

DOI: https://doi.org/10.1002/hep.31187

IF: 17.298

Hepatology

Abstract:Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhosis and additional comorbidities. The "stage hierarchy" approach, which involves linking each stage (or substage) of the disease to a specific treatment, has become the main proposed treatment strategy for the clinical management of HCC, particularly in the West. The Barcelona Clinic Liver Cancer (BCLC) scheme serves as the main example of the application of this strategy. In an attempt to increase the plasticity of the "stage hierarchy" approach as well as its adaptability to the requirements of real-world clinical practice, the latest versions of European and American guidelines have introduced certain relevant elements of flexibility, which were not intrinsic to the original BCLC scheme. These elements are as follows: the "treatment stage migration" strategy, which allows moving to another treatment (generally the one that is associated with the subsequent stage) if the approach linked with the current stage proves to be unfeasible, and the "treatment stage alternative" approach, which proposes further therapeutic options for each BCLC-defined stage. In regard to most of the solid cancers, another potential strategy is to consider the treatment decision to be hierarchically dictated by the efficacy of each therapy with complete or partial independence from the tumor stage. This concept of "therapeutic hierarchy" has been historically endorsed by the Asia-Pacific treatment algorithm as well as by the recent Italian multisociety guidelines. The present review provides a critical analysis of the different conceptual approaches to HCC management, highlighting their advantages and disadvantages and focusing on the remarkable differences between the stage-guided and the hierarchical strategies.
A modified Charlson Comorbidity Index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine

E. Alimenti,M. Iavarone,L. Canova,E. Fracas,B. Antonelli,A.M. Ierardi,S. Crespi,A. Zefelippo,A. Sangiovanni,P. Lampertico

DOI: https://doi.org/10.1016/j.dld.2024.01.142

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Background & aims Patients with hepatocellular carcinoma (HCC) frequently have comorbidities that limit access to treatments and might increase mortality. The Charlson comorbidity index (CCI) assigns a numeric score to 17 diseases according to their effect on mortality. In patients with cirrhosis and HCC, these variables might be excluded from the CCI (modified CCI, mCCI). Aim of the study was to evaluate the performance of CCI and mCCI for HCC patients’ characterization. Methods We used data from our retrospective monocentric study of patients with first HCC diagnosis. We evaluated the performance of CCI and mCCI in dissecting our population and predicting overall survival (OS). As secondary end-point, the impact of mCCI on adherence to Barcelona Clinic Liver Cancer (BCLC) staging and treatment allocation was evaluated. Results The study included 385 patients (289 males, 68 years median age, 78% Child Pugh (CPT) A, 66% viral etiology) with HCC (271 BCLC 0/A, 64 B, 40 C and 10 D). According to CCI, 94% of our patients were “high-risk” (CCI≥5), 5.7% “intermediate-risk” (CCI 3-4) and 0.3% “low-risk” (CCI 0-2). These cutoffs were applied to mCCI: 21% “high-risk”, 48% “intermediate-risk”, and 31% “low-risk”. Patients' mCCI correlated with CCI (Kendall's τ=0.47; p-value< 0.0001). Overall, patients belonging to a “high” or “intermediate-risk” mCCI classes had a shorter OS as compared to “low-risk” patients (median OS 37 vs 49 vs 67 months, p-value=0.007). This was confirmed in BCLC 0/A (p-value=0.002). Moreover, “high-risk” mCCI class, worse CPT class, presence of varices, BCLC stage and AFP>200 ng/mL were independently associated to mortality [HR1.36 (95%CI 1.09-1.70, p-value=0.006; HR1.62 (95%CI 1.14-2.30), p-value=0.007; HR1.58 (95%CI 1.11-2.24), p-value=0.01; HR1.96 (95%CI 1.66-2.31) p-value<0.001; HR1.80 (1.17-2.79) p-value=0.008]. mCCI was also an independent predictor of mortality in BCLC 0/A, with higher tumor burden and worse CPT. No differences were observed in adherence to BCLC2022 algorithm and access to treatment among the mCCI risk classes. Conclusions mCCI better stratified patients with HCC as compared to CCI and independently predicted mortality. Implementation of a multiparametric therapeutic approach to treatment allocation including evaluation of comorbidities and frailty is warranted.

gastroenterology & hepatology
Information as a quantitative creiterion of biospheric evolution.

G. Theodoridis,L. Stark

IF: 64.8

Nature

Abstract:
Beta-lactoglobulin structure and retinol binding changes in presence of anionic and neutral detergents.

A. Taheri‐Kafrani,A. Bordbar,Seyed Habib-Allah Mousavi,T. Haertlé

DOI: https://doi.org/10.1021/jf801179k

IF: 6.1

2008-08-27

Journal of Agricultural and Food Chemistry

Abstract:Bovine beta-lactoglobulin (beta-LG) in vivo (in milks) has been found in complexes with lipids such as butyric and oleic acids. To elucidate the still unknown structure-function relationship in this protein, the structural changes of beta-lactoglobulin variant A (beta-LG A) in the presence of anionic surfactant such as sodium n-dodecyl sulfate (SDS) and in the presence of nonionic surfactant such as Triton X-100 have been investigated. Subsequently, the retinol binding by beta-LG has been investigated in the presence of various amounts of these surfactants as its binding indicator. The results of UV-vis and fluorescence studies show a higher denaturating effect of SDS at acid pH that can be due to greater positive charges of beta-LG at this pH indicating also the nonspecific hydrophobic interactions of Triton X-100 with beta-LG at all studied pHs. Isothermal titration calorimetry (ITC) measurements indicate the endothermic nature of beta-LG/SDS interactions and the exothermic nature of Triton X-100/beta-LG interactions. The analysis of the binding data demonstrates the absence of considerable changes in retinol binding properties of beta-LG in the presence of various amounts of these surfactants. This implies that surfactant binding does not change the conformation of beta-LG in the regions defining the retinol-binding site.
Multimodality treatment and two-stage resection for unresectable hepatocellular carcinoma--experimental and clinical studies]

Z Y Tang

1990-01-01

Abstract:During the period 1978-1987, 255 patients with pathologically proven hepatocellular carcinoma (HCC) were assessed to be unresectable by laparotomy. Of them 155 had their tumors chiefly confined in the right or left lobe. Second stage resection was performed in 26 (16.8%) after marked reduction of the tumor by combination treatment with hepatic artery ligation (HAL) + hepatic artery infusion chemotherapy (HAI) + multifractionated radiotherapy (MFD) with linear accelerator, or radioimmunotherapy using 131I-anti human HCC ferritin antibody (131I-FtAb), which yielded the highest second stage resection rate (29.8%, 14/47) as compared to HAL + HAI or HAL + cryosurgery (16.9%, 12/71), HAL or HAI (0%, 0/37) alone. The 3 year survival rate of the 26 patients with second stage resection was 74.3%, comparable with those of small HCC resection (82.7%, n = 111) and radical resection of large HCC (56.1%, n = 122) in the same period. Experimental study using nude mice bearing human HCC also showed the superiority of triple (MFD or 131I-FtAb + Cisplatin PDD + mixed bacterial vaccine MBV) versus double (MFD or 131I-FtAb + PDD, or MFD or 131I-FtAb + MBV) and double versus single treatment modality. Both experimental and clinical data indicated that immunosuppression after radiotherapy was prevented by adjuvant immunotherapy (MBV). Thus, this treatment model provides an opportunity for resection or even cure in a part of patients with unresectable HCC confined in one lobe.
Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future

Sang-Youn Hwang,Hyunwook Choi,Wan Jeon,Ryoung-Go Kim

DOI: https://doi.org/10.17998/jlc.2024.08.30

Abstract:Downstaging of hepatocellular carcinoma (HCC) is typically defined as the reduction in size or number of viable tumors through locoregional therapy (LRT), aiming to meet the established criteria for liver transplantation (LT). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, a subgroup of patients with BCLC-B may benefit most from downstaging therapies. The United Network Organ Sharing downstaging protocol identifies potential candidates for downstaging by setting out 'inclusion criteria' and defining 'successful downstaging.' Additionally, the protocol considers factors related to tumor biology, such as an alphafetoprotein level <500 ng/mL after LRT. Reports indicate that successful downstaging rates following LRT are about 50%, with post- LT recurrence rates comparable to those of patients within the Milan criteria. A comprehensive multicenter US study on 10-year outcomes post-LT after downstaging showed 10-year post-LT survival and recurrence rates of 52.1% and 20.6%, respectively, for patients whose disease was downstaged; this compares to 61.5% and 13.3% for those consistently within the Milan criteria. Recently, the development of effective systemic treatments for HCC, such as immuno-oncologic agents, has provided additional opportunities for downstaging. Numerous clinical trials are exploring a multidisciplinary approach (MDA) combining LRT and systemic therapy. Although concrete evidence of the superiority of MDA for HCC downstaging is lacking, some retrospective studies and phase I and II trials have shown promising results regarding the efficacy and safety of MDA for this purpose. In this review, we will also discuss the future of MDA protocols in downstaging for improved clinical outcomes.
Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis

John Hang Leung,Shyh-Yau Wang,Henry W. C. Leung,Agnes L. F. Chan

DOI: https://doi.org/10.3389/fonc.2024.1344798

IF: 4.7

2024-02-17

Frontiers in Oncology

Abstract:Background: Portal vein tumor thrombus (PVTT) is a common complication and an obstacle to treatment, with a high recurrence rate and poor prognosis. There is still no global consensus or standard guidelines on the management of hepatocellular carcinoma (HCC) with PVTT. Increasing evidence suggests that more aggressive treatment modalities, including transarterial chemoembolization, radiotherapy, targeted therapy, and various combination therapies, may improve the prognosis and prolong the survival of advanced hepatocellular carcinoma (aHCC) patients with PVTT. We aim to comprehensively review and compare the efficacy and safety of these advanced options for aHCC with PVTT. Methods: A comprehensive literature search was conducted on PubMed and EMBASE for phase II or III randomized controlled trials (RCTs) investigating multimodality treatments for aHCC with PVTT. Kaplan–Meier curves for overall survival (OS) and progression-free survival were constructed to retrieve individual patient-level data to strengthen the comparison of the benefits of all multimodality treatments of interest. Each study was pooled in a fixed-effects network meta-analysis (NMA). We also conducted subgroup analyses using risk ratios extracted from each study, including viral etiology, Barcelona Clinic Liver Cancer (BCLC) staging, alpha-fetoprotein (AFP) levels, macrovascular invasion or portal vein tumor thrombosis, and extrahepatic spread. Multimodality treatments were ranked using SUCRA scores. Results: We identified 15 randomized controlled trials with 16 multimodality regimens that met the inclusion criteria. Among them, 5,236 patients with OS results and 5,160 patients with PFS results were included in the analysis. The hepatic arterial infusion chemotherapy of fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) showed OS and PFS benefits over all the other therapies. In terms of OS, HAIC-FO, nivolumab, and TACE+Len were superior to sorafenib, lenvatinib, and donatinib monotherapies, as well as HAIC-FO+Sor. In terms of PFS, TACE+Len showed better benefits than lenvatinib, donatinib, and tremelimumab+durvalumab. A low heterogeneity ( I 2 < 50%) and consistency were observed. The SUCRA score for OS ranked HAIC-FO+sorafenib as the best treatment option among all multimodality treatments in hepatitis B, MVI, or PVTT with EHS and AFP 400 μg/L subgroups. Conclusion: HAIC-FO and HAIC-FO+sorafenib are statistically better options for unresectable hepatocellular carcinoma with PVTT among the multimodality treatments, and their effective and safe implementation may provide the best outcomes for HCC-PVTT patients.

oncology
SNAREs and the secretory pathway-lessons from yeast.

H. Pelham

DOI: https://doi.org/10.1006/EXCR.1998.4356

IF: 4.145

1999-02-25

Experimental Cell Research

Abstract:SNARE proteins lie at the heart of the membrane fusion events in the secretory and endocytic pathways. Physical interactions between them are thought not only to provide the driving force for bringing membranes together, but also to contribute to the specificity of vesicle targeting. Completion of the yeast genome sequence has allowed the full set of SNAREs to be identified. Characterization of these helps to define the number of distinct compartments and the nature of the transport steps between them, but also shows that SNAREs are by no means the sole determinants of fusion specificity. Evolutionary conservation of SNAREs suggests that despite the differences in scale and morphology, many features of membrane organization are similar in yeast and animal cells. This review summarizes current knowledge of the yeast SNAREs and the picture of the secretory pathway that emerges from such studies.
Current management of hepatobiliary malignancies between centers with or without a liver transplant program: A multi-society national survey

Matteo Serenari,Roberta Angelico,Quirino Lai,Damiano Patrono,Irene Scalera,Emanuele Kauffmann,Duilio Pagano,Riccardo De Carlis,Enrico Gringeri,Alessandro Vitale,AICEP-SITO-CCTF study group,Adelmo Antonucci,Alberto Brolese,Alberto Patriti,Aldo Rocca,Alessandro Ferrero,Alessandro Iacomino,Amedeo Carraro,Andrea Ruzzenente,Antonio Frena,Antonio Giuliani,Bruno Nardo,Christian Cotsoglou,Edoardo Saladino,Elio Jovine,Enzo Andorno,Ettore Colangelo,Fabrizio Di Benedetto,Fabrizio Romano,Fausto Zamboni,Felice Giuliante,Francesco Izzo,Francesco Tandoi,Fulvio Calise,Giacomo Zanus,Gian Luca Baiocchi,Gian Luca Grazi,Giorgio Ercolani,Giovanni Vennarecci,Giuseppe Maria Ettorre,Giuseppe Tisone,Guido Griseri,Guido Torzilli,Leonardo Vincenti,Lorenzo Livraghi,Luca Aldrighetti,Luca Morelli,Luca Vigano,Luciano De Carlis,Lucio Caccamo,Lucio Urbani,Luigi Boccia,Luigi Veneroni,Marcello Giuseppe Spampinato,Marcello Maestri,Marco Massani,Marco Spada,Marco Vivarelli,Massimo Fedi,Massimo Rossi,Matteo Barabino,Matteo Cescon,Matteo Donadon,Matteo Ravaioli,Michele Achille Crespi,Michele Ciocca Vasino,Michele Colledan,Michele Mazzola,Mohammed Abu Hilal,Nazario Portolani,Nicola Cinardi,Paola Tarchi,Paolo De Simone,Raffaele Dalla Valle,Renato Romagnoli,Riccardo Memeo,Roberto Lauro,Roberto Santambrogio,Roberto Troisi,Salvatore Gruttadauria,Salvatore Agnes,Silvio Guerriero,Stefano Berti,Ugo Boggi,Umberto Baccarani,Umberto Cillo,Vincenzo Mazzaferro

DOI: https://doi.org/10.1016/j.dld.2024.09.007

2024-10-07

Abstract:Background: Availability of liver transplantation (LT) as a treatment for hepatocellular carcinoma (HCC) and other liver malignancies may determine heterogeneity of therapeutic strategies across different centers. Aims: To investigate the practice between hepato-biliary centers without (HB centers) and with a LT program (LT centers), we launched a 38-item web-based national survey, with directors of centers as a target. Methods: The survey, including 4 clinical vignettes, collected data on their approach to HCC and transplant oncology. Results: After duplicates removal, 75 respondents were considered. Respondents from LT centers (n = 22, 29.3 %) were more in favor of LT in the case of HCC outside Milan criteria (90.9 % vs. 67.9 %, p = 0.037), recurrent HCC (95.5 % vs. 50.9 %, p = 0.002) and other malignancies such as cholangiocarcinoma or neuroendocrine tumors. No significant difference was observed concerning the proportion of centers favorable to LT for unresectable colorectal liver metastases (100 % vs. 88.7 %, p = 0.100). Conclusion: This national survey showed how management of HCC and awareness of transplant oncology may differ between HB and LT centers. Effective networking between HB and LT centers is crucial to provide optimal treatment and access to LT.

Biology and pathogenesis of the myelodysplastic syndromes.

Treatment of hepatocellular carcinoma: beyond international guidelines

Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study

Hyperpolarization-activated inward chloride current in protoplasts from suspension-cultured carrot cells

Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice

Compliance to the American Association for the Study of Liver Diseases (AASLD) guidelines and its impact on overall survival in patients with hepatocellular carcinoma.

Hepatoma Today: Therapeutic Experiences of Multimodal Approach

Multimodal treatment confers best overall survival results in patients with huge hepatocellular carcinoma: a systematic review and network meta-analysis

Clinical events after TIPS: correlation with hemodynamic findings.

Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective

Merits and boundaries of the Barcelona Clinic Liver Cancer Staging and Treatment Algorithm: learning from the past to improve the future with a novel proposal.

A Multidisciplinary Team Approach to the Treatment of Liver Cirrhosis

Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy

A modified Charlson Comorbidity Index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine

Information as a quantitative creiterion of biospheric evolution.

Beta-lactoglobulin structure and retinol binding changes in presence of anionic and neutral detergents.

Multimodality treatment and two-stage resection for unresectable hepatocellular carcinoma--experimental and clinical studies]

Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future

Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis

SNAREs and the secretory pathway-lessons from yeast.

Current management of hepatobiliary malignancies between centers with or without a liver transplant program: A multi-society national survey